Current filters:


Popular Filters

7820 to 7844 of 8766 results

Key hospital-infections markets set to grow to over $4 billion in 2020; report


Despite market constraints that include intensified competition, generic erosion and an increasingly…

Antibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceutical

Denmark’s Novo Nordisk partners to tackle Qatar’s diabetes problem


According to Danish insulin giant Novo Nordisk (NVO: N) diabetes is on the rise in Qatar and poses a…

DiabetesHealthcareNovo NordiskPharmaceuticalRest of the World

FDA approves Transcept Pharma’s Intermezzo mid-night insomnia treatment


US drugmaker Transcept Pharmaceuticals (Nasdaq: TSPT) saw its shares jump 11% to $7.34 yesterday, after…

IntermezzoNeurologicalNorth AmericaPharmaceuticalPurdue PharmaRegulationTranscept Pharmazolpidem

AEterna Zentaris signs up Hikma to commercialize perifosine in MENA region


Canada’s AEterna Zentaris (TSX: AEZ) has signed an exclusive commercialization and licensing agreement…

AEterna ZentarisGenericsHikma PharmaceuticalsLicensingOncologyperifosinePharmaceuticalRest of the World

UK’s NICE gives preliminary “no” to Novartis’ Lucentis for macular edema


In preliminary recommendations published today (November) 24 by the UK drugs watchdog the National Institute…


Asahi Kasei Pharma expands into USA with acquisition of Artisan Pharma


Mid-size Japanese drugmaker Asahi Kasei Pharma says it has acquired its US licensee Artisan Pharma, establishing…

Artisan PharmaAsahi KaseiMergers & AcquisitionsPharmaceuticalRecomodulin

Celgene to drop Revlimid in CR prostate cancer following Ph III trial failure


There was disappointment for blockbuster for multiple myeloma drug Revlimid (lenalidomide) when the Swiss…


Problems identified in Canada’s drug regulatory system


A report presented to the Canadian Parliament this week by John Wiersema, Interim Auditor General of…

North AmericaPharmaceuticalRegulation

EMA makes interim recommendations to deal with shortcomings at Ben Venue Labs


The European Medicines Agency (EMA) is currently reviewing shortcomings in quality assurance identified…

Boehringer IngelheimEuropeMarkets & MarketingNorth AmericaPharmaceuticalRegulation

Indian HIV drugs market forecast to reach $54 million by 2014


The market for HIV drugs in India is expected to reach 454 million by 2014, according to a new report…

Anti-viralsAsia-PacificGenericsMarkets & MarketingPharmaceutical

Merck & Co to pay $950 million for illegal marketing of Vioxx


US pharma giant Merck & Co (NYSE: MRK) has agreed to pay $950 million to resolve criminal charges and…

FinancialLegalMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalVioxx

Pfizer to buy Excaliard, gaining rights to Ph II skin scarring product


Global pharma behemoth Pfizer (NYSE: PFE) says it has entered into a definitive agreement to acquire…

DermatologicalsExcaliard PharmaIsis PharmaceuticalsMergers & AcquisitionsPfizerPharmaceutical

UCB adds to CNS portfolio with acquisition of Lectus’ key pharmaceutical assets


Belgian drugmaker UCB (Euronext Brussels: UCB) has acquired the key pharmaceutical assets of closely-held,…

Lectus TherapeuticsMergers & AcquisitionsNeurologicalPharmaceuticalResearchUCB

FDA accepts NDA for Lundbeck and Otsuka’s aripiprazole depot formulation


Danish CNS drug specialist Lundbeck (LUND: DC) and its new partner Japan’s Otsuka Pharmaceutical…

aripiprazole depotLundbeckNeurologicalNorth AmericaOtsukaPharmaceuticalRegulation

Novartis gains NIH listing in Japan for Ilaris


Swiss drug major Novartis’ (NOVN: VX) Ilaris (canakinumab), a treatment for cryopyrin-associated…

Anti-Arthritics/RheumaticsAsia-PacificIlarisNovartisPharmaceuticalPricingRare diseases

Andromeda’s type 1 diabetes candidate DiaPep277 meets Ph III primary endpoint


Israel-based Andromeda Biotech, a subsidiary of Clal Biotechnology Industries (TASE: CBI.TA), says initial…

AndromedaBiotechnologyClal BiotechnologyDiabetesDiaPep277ResearchTeva Pharmaceutical Industries

Promotions at Par Pharma as firm grows with acquisitions


US generics drugmaker Par Pharmaceutical (NYSE: PRX) has promoted Thomas Haughey to the role of president…

GenericsManagementPar Pharmaceutical

New Australian paper shows need to complete clinical trial plan


A Medicines Australia paper launched at Parliament House yesterday (November 22) shows the federal government’s…


Gilead expands hepatitis C R&D portfolio with $11 billion buy of Pharmasset


In its biggest M&D deal to date, Gilead Sciences (Nasdaq: GILD) says it has signed a definitive agreement…

Anti-viralsBiotechnologyGilead SciencesMergers & AcquisitionsmericitabinePharmaceuticalPharmasset

Valeant to acquire Australia’s iNova for up to $946 million


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (NYSE: VRX and TSX: VRX) has signed…

BiotechnologyiNovaMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

7820 to 7844 of 8766 results

Back to top